SGLT2 inhibitor monotherapy alleviates hyperglycemia in heredity severe insulin resistance syndrome  

作　　者：Huixuan Wu Junaid Iqbal Long Li Hongli Jiang Chen Chao Meibiao Zhang Ou Li Houde Zhou 

机构地区：[1]Department of Metabolism and Endocrinology,National Clinical Research Center for Metabolic Diseases,Hunan Provincial Key Laboratory for Metabolic Bone Diseases,Key Laboratory of Diabetes Immunology,Ministry of Education,The Second Xiangya Hospital of Central South University,Changsha,Hunan 410011,China [2]Department of Endocrinology and Metabolism,The First People’s Hospital of Huaihua,Huaihua,Hunan 418000,China [3]Department of Metabolism and Endocrinology,San-Sui County Traditional Chinese Medicine Hospital,Qiandongnan Miao and Dong Autonomous Prefecture,Guizhou 556000,China

出　　处：《Chinese Medical Journal》2024年第11期1372-1374,共3页中华医学杂志（英文版）

基　　金：National Natural Science Foundation of China(Nos.8217033609,81770880,and 81970762);Science&Technology Department of Hunan Province(Nos.2020SK2080 and 2015JC3012);Science&Technology Department of Changsha City(Nos.k1906019 and kq190111)

摘　　要：To the Editor:Hereditary severe insulin resistance syndrome(H-SIRS)shows a wide and variable clinical spectrum and results in severe complications in the endocrinological and cardiovascular systems.Multiple treatments are recommended to control hyperglycemia in H-SIRS,including dietary intervention,insulin therapy,insulin sensitization,and recombinant human insulin-like growth factor-1(rhIGF-1)administration.[1]However,the heterogeneous etiology of H-SIRS leads to poor glycemic control in patients with different mutations,requiring multiple antihyperglycemic medications.This study described two cases diagnosed with H-SIRS and the treatment effect of multi-drug therapy and sodium-glucose cotransporter 2 inhibitor(SGLT2i)monotherapy.

关 键 词：SIRS CARDIOVASCULAR clinical 

分 类 号：R587.1[医药卫生—内分泌]